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Abstract
Background: Thoracic pathologists are frequently faced with tissue specimens from intrathoracic/mediastinal
tumors. Specifically the differentiation between thymic and pulmonary squamous cell carcinomas (SqCC) can be
challenging. In order to clarify the differential diagnostic value of CD5 and CD117 in this setting, we performed a
large scale expression study of both markers in 1465 non-small cell lung cancer (NSCLC) cases.
Methods: Tissue microarrays of formalin-fixed paraffin-embedded resection specimens of 1465 NSCLC were stained
with antibodies against CD117 and CD5. Positivity of both markers was correlated with clinicopathological variables.
Results: CD117 was positive in 145 out of 1457 evaluable cases (9.9 %) and CD5 was positive in 133 out of 1427
evaluable cases (9.3 %). 28 cases (1.9 %) showed coexpression of CD117 and CD5. Among the 145 cases that were
positive for CD117, 97 (66.8 %) were adenocarcinomas (ADC), 34 (23.4 %) were SqCC, 5 (3.4 %) were
adenosquamous carcinomas (ADSqCC), 8 (5.5 %) were large cell carcinomas (LC), and one (0.6 %) was a
pleomorphic carcinoma (PC). In the CD5 positive group consisting of 133 cases, 123 (92.4 %) were ADC, 0 (0 %)
were SqCC, 4 (3.0 %) were ADSqCC, 3 (2.2 %) LC and 3 (2.2 %) were PC. None of the 586 SqCC showed expression
of CD5. No association of CD117- or CD5 positivity to patients’ age, pathological stages or to T-, N-, or M-
categories was observed.
Conclusions: A substantial subset of NSCLC exhibit positivity of CD117 and CD5. Since CD5 expression was not
observed in pulmonary SqCC, but is expressed in the majority of thymic squamous cell carcinomas, the application
of this immunomarker is a valuable tool in the differential diagnosis of thoracic neoplasms.
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Background
Comprehensive morphological and immunohistochem-
ical subtyping of tumors is of growing importance for
therapy selection and propelled the concept of a
tumor-specific, individualized treatment. For non-
small cell lung cancer (NSCLC) the current WHO
Classification [1] therefore extended the concept of
immunophenotyping from biopsies to resection speci-
mens. However, the vast majority of NSCLC cases re-
main non-resectable at initial diagnosis where often
only small biopsies or even cytology material is avail-
able. Thoracic pathologists are frequently faced with
tissue specimens from central tumors with medias-
tinal involvement. In this setting it is particularly
challenging to distinguish pulmonary from thymic pri-
maries [2]. With approximately 80 % [3, 4] the most
common phenotype of malignant thymic tumors is
squamous cell carcinoma; thus, the differentiation of
squamous cell carcinoma of the lung (SqCC) is
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challenging. However, differentiation of both is of
high clinical importance since therapies differ sub-
stantially [5] and thymic carcinomas are associated
with a better prognosis [6]. Since thymic tumors show
a high variability with respect to their phenotype [7],
but occur with low frequency, the establishment of
specific immunomarkers for the differential diagnostic
setting requires large scale phenotyping approaches.
CD117 [8, 9] and CD5 [10–13] are well-known diag-
nostic markers for thymic carcinomas and are fre-
quently used to separate thymomas from thymic
squamous cell carcinomas. However, data on both
markers in NSCLC is limited. In order to clarify the
differential diagnostic value of CD117 and CD5 to
separate between pulmonary and thymic primaries,
we performed a large scale expression study of both
markers in 1465 NSCLC and correlated the findings
with common clinicopathological variables.
Methods
Cohort characteristics and TMA construction
Formalin-fixed paraffin-embedded specimens of
NSCLC resected from 2002 to 2010 at the Thoraxklinik at
Heidelberg University were extracted from the archive of
the Institute of Pathology, Heidelberg University with the
support of the tissue bank of the National Center for
Tumor Diseases (NCT: project: # 1283). Tissues were
used in accordance with the ethical regulations of the
NCT tissue bank established by the local ethics commit-
tee. A cohort of 1465 patients was identified for TMA
construction. Diagnoses were made according to the rec-
ommendations of the World Health Organization classifi-
cation for lung cancer 2015 [1, 14]. Prior to TMA
construction, a hematoxylin and eosin (H&E)-stained slide
of each block was analyzed in order to select representa-
tive tumor-containing regions. A TMA machine (Alpha-
Metrix Biotech, Rödermark, Germany) was used to
extract a tandem 1.0 mm cylindrical core sample from
each tissue donor block. The cohort characteristics are
summarized in Table 1.
Immunohistochemistry
Immunohistochemistry (IHC) was performed with com-
mercially available antibodies (Additional file 1: Table
S1) and was applied according to quality-controlled pro-
tocols that are regularly evaluated in round robin trials
(http://www.nordiqc.org). In brief, TMA slides were
deparaffinized and pretreated with antigen retrieval buf-
fer. Subsequent steps were performed on an immuno-
staining device (Ventana BenchMark Ultra, Tuscon,
USA). Pretreatment and dilution specifications are sum-
marized in Additional file 1: Table S1. Evaluation of IHC
was performed blinded to the resection specimen diag-
noses, according to a dichotomous scoring scheme [15].
1 % stained tumor cells were considered to indicate posi-
tivity. Each tumor from a patient was represented by
two cores on the respective TMA; both cores were ana-
lyzed together.
Statistics
Data analysis was performed using R statistical software
(v. 3.2.2) and RStudio (v. 0.98.507). Barplots were cre-
ated with the ggplot2-package (v. 1.0.1) and dependen-
cies. T-test was applied to examine differences in age.
Fisher’s exact test of independence or Freeman-Halton
test was applied to compare between histotypes, T-, N-
and M- categories and clinical stage. A p-value <0.01
was considered statistically significant.
Results
Patient characteristics
Clinicopathological data of 1465 NSCLC cases (stage IA-
IV) were analyzed. The median age at diagnosis was
64 years (range: 30–89 years). The majority of patients
were male (69.3 %). 711 patients were diagnosed with
adenocarcinoma (ADC; 48.5 %), 586 patients with squa-
mous cell carcinoma (SqCC; 40.0 %), 55 patients with
adenosquamous carcinoma (AdSqCC; 3.8 %), 71 patients
with large cell carcinoma (LC; 4.8 %) and 42 patients
with pleomorphic carcinoma (PC; 2.9 %), respectively.
Neither CD117 positivity, nor CD5 positivity correlated
to patients’ age (p = 0.79 and p = 0.13), any T- (p = 0.07
and p = 0.02), N- (p = 0.16 and p = 0.03) and M-categories
(p = 0.42 and p = 0.77) or clinical stage (p = 0.32 and
p = 0.05).
Expression of CD117 and CD5 in NSCLC
In 46 patients (3.1 %) CD117 and/or CD5 could not be
evaluated because there were either no vital tumor cells
or lost tissue cores during the staining process.
Both, CD117 and CD5 showed diffuse membranous
and cytoplasmic positivity (Fig. 1). CD117 was positive
in 145 out of 1457 evaluable cases (9.9 %) and CD5 was
positive in 133 out of 1427 evaluable cases (9.3 %). 28
cases (1.9 %) showed coexpression of CD117 and CD5
(Table 1).
Among the 145 CD117 positive cases, 97 (66.8 %)
were ADC, 34 (23.4 %) were SqCC, 5 (3.4 %) were
ADSqCC, 8 (5.5 %) were LC, and one (0.6 %) was a PC.
The frequency of CD117 positive tumors was higher
in ADC than in any other histotype (p < 0.01).
In the CD5 positive group consisting of 133 cases, 123
(92.5 %) were ADC, 0 (0 %) were SqCC, 4 (3.0 %) were
ADSqCC, 3 (2.2 %) were LC and 3 (2.2 %) were PC. The
frequency of CD5 positive tumors was higher in ADC
than in any other histotype (p < 0.01). No SqCC showed
expression of CD5.
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In the 28 cases that exhibited coexpression of CD117
and CD5, 26 were ADC (92.8 %), one was ADSqCC
(3.5 %) and one was a LC (3.5 %). Again, CD5/CD117
coexpression was significantly more frequent in ADC
than in any other histotype (p < 0.01). CD5 and CD5/
CD117 positive patients were more often male (p < 0.01).
Application of the immunoreactive score by Remmele et
Stegner [16] could not improve the diagnostic power of
any category. A summary of IHC findings is provided in
Table 1 and Fig. 2.
Discussion
This is the largest study analyzing the expression of CD5
and CD117 in NSCLC. We demonstrate that positivity
for both markers is evident in approximately 10 % of all
NSCLC and is predominantly found in ADC. While
coexpression of CD5 and CD117 is rare and also pre-
dominates in ADC, the coexpression of both markers
was not detected in SqCC. Likewise none of the SqCC
showed CD5 expression. Thus, a marker panel including
CD5 and CD117 is helpful in the differential diagnosis of
Table 1 Basic clinicopathological characteristics of the analyzed NSCLC cohort
Clinicopathological Variables CD117 p-value CD5 p-value CD117/CD5 p-value
positive negative positive negative positive negative
Mean age at surgery 63 years 63 years 63 years p = 0.79 62 years 63 years p = 0.13 61 years 63 years p = 0.25
Patient gender
Male 1016 (69.3 %) 89 921 p = 0.03 76 910 p < 0.01 14 852 p < 0.01
Female 448 (30.5 %) 56 390 57 383 10 356
Histology
Adenocarcinoma 711 (48.5 %) 97 611 p < 0.01 123 564 p < 0.01 26 685 p < 0.01
Squamous Cell Carcinoma 586 (40.0 %) 34 548 0 575 0 586
Adenosquamous Carcinoma 55 (3.8 %) 5 49 4 50 1 54
Large Cell Carcinoma 71 (4.8 %) 8 63 3 67 1 70
Pleomorphic Carcinoma 42 (2.9 %) 1 41 3 38 0 42
TNM-Classification
pT1a 125 (8.5 %) 21 102 p = 0.07 16 103 p = 0.02 4 121 p = 0.10
pT1b 158 (10.8 %) 19 138 20 135 5 153
pT2a 641 (43.8 %) 62 578 64 554 15 626
pT2b 245 (16.7 %) 22 221 16 228 2 243
pT3 248 (16.9 %) 17 230 13 230 1 247
pT4 48 (3.3 %) 4 43 4 44 1 47
pN0 755 (51.5 %) 83 667 p = 0.16 80 651 p = 0.03 16 739 p = 0.57
pN1 353 (24.0 %) 27 324 15 330 2 351
pN2 351 (23.9 %) 35 315 38 309 10 341
pN3 6 (0.4 %) 0 6 0 4 0 6
pM0 1426 (97.3 %) 143 1275 p = 0.42 129 1261 p = 0.77 27 1399 p = 0.53
pM1a 6 (0.4 %) 0 6 2 4 1 5
pM1b 33 (2.3 %) 2 31 2 29 0 33
Clinical stage
I A 190 (12.9 %) 25 162 p = 0.32 25 156 p = 0.05 6 184 p = 0.48
IB 344 (23.5 %) 32 312 38 293 7 337
IIA 277 (18.9 %) 28 248 15 259 3 274
IIB 165 (11.3 %) 18 145 11 152 1 164
IIIA 422 (28.8 %) 40 380 39 376 11 411
IIIB 29 (1.9 %) 0 29 2 25 0 29
IV 38 (2.6 %) 2 36 3 33 0 38
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primary lung and primary thymic squamous cell carcin-
omas with coexpression as a strong argument for a
thymic primary.
Tumors of the mediastinum have a broad differential
diagnosis ranging from benign disorders such as thyroid
goiter or bronchogenic cysts to malignant diseases such
as lymphoma, esophageal cancer or metastases from dis-
tant primaries [2]. Although routine thoracic imaging
often initiate the subsequent evaluation of a mediastinal
mass, it is rarely diagnostic and a biopsy is usually re-
quired to establish a definitive diagnosis. Albeit many
entities have characteristic properties on H&E staining,
tumor subtyping remains challenging in some cases and
additional IHC stainings are necessary for a final clas-
sification. Specifically in the setting of central thoracic
neoplasms the differentiation of thymic carcinomas
from NSCLC with mediastinal involvement can be
difficult [12, 17]. Immunostaining against CD117, a
Fig. 1 Representative immunohistological stainings of CD117 and CD5 in ADC and SqCC. Representative images of ADC of the lung show CD5
(a) and CD117 (c) positive and negative cases (b, d). Moreover, a CD117 (e) positive and CD117 (f) negative SqCC is illustrated
Fig. 2 CD117 and CD5 positivity according to NSCLC histotype. A barplot of the absolute number of CD117- (lightblue), CD5- (blue) and CD117/
CD5 (darkblue) positive NSCLC cases is shown according to the specific histotype. ADC: adenocarcinoma, SqCC: squamous cell carcinoma,
ADSqCC: adeno-squamous carcinoma, LC: large cell carcinoma and PC: pleomorphic carcinoma
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transmembrane tyrosine kinase receptor, and against
CD5, a member of the ancient scavenger receptor
superfamily, is routinely performed to separate thym-
oma from thymic carcinoma. While CD117 is positive
in approximately 85 % of thymic carcinomas, CD5 is
positive in approximately 70 %, and about 60 % of cases
show a CD117 and CD5 positive phenotype [8–10]. Thus,
positivity of both markers support a diagnosis of thymic
carcinoma. While several studies have investigated the ex-
pression of both markers in thymic carcinomas [8–12,
18–20], knowledge on the prevalence in large scale
NSCLC cohorts is limited. Hence, we questioned if these
markers might also be helpful in the differential diagnosis
to NSCLC.
Albeit most studies revealed CD117 positivity in 20 %
[9, 18, 21] of NSCLC cases, a wide range varying from
7 % [22] to 64 % [23] has been reported, mainly due to
different cut-offs applied. Since positive or negative is
the most important diagnostic aspect and cut-offs are
usually not helpful in the interpretation of diagnostic
IHC markers in small biopsies, we used a dichotomous
scoring scheme. Moreover, CD117 has been suggested to
be a prognostic marker for NSCLC. However, data is
conflicting since some studies [22–24] demonstrated a
prognostic effect of CD117 positivity in NSCLC but
others could not confirm this finding [25]. In the present
study we found CD117 in 145 out of 1457 (9.9 %)
NSCLC which matches the reported range. Most CD117
positive tumors were ADC (66.9 % of all CD117 positive
cases), followed by SqCC (23.4 %) which is well in line
with the available literature [18].
CD5 has been investigated in NSCLC before and
found to be present in 0–85 % of cases [9, 10, 21]. CD5
positivity has been detected in a substantial subset of
ADC in one study, but the results were limited by a ra-
ther small number of ADC investigated (n = 20) [21].
With regard to CD5 expression, a lack of representative
large cohorts is also evident and the prevalence in
NSCLC is unclear so far [9, 10, 21]. In this large scale
study we found CD5 positivity in NSCLC in 133 out of
1427 NSCLC (9.2 %). Coexpression of CD117 and CD5
was detected in 28 out of 1465 cases (1.9 %) and was re-
stricted to ADC, ADSqCC and LC. CD5 expression was
not present in any of the 578 SqCC cases. Thus, CD5 or
CD117/CD5 coexpression in a upper mediastinal tumor
is a strong argument for a thymic primary and argues
against SqCC of the lung.
Conclusions
In summary, we demonstrate on 1465 NSCLC cases
that a substantial subset exhibit CD117 and CD5
positivity and that pulmonary SqCC are consistently
negative for CD5. Thus, the application of both
immunomarkers is a valuable tool in the differential
diagnosis of mediastinal tumors.
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